BACKGROUND: C-reactive protein (CRP) increases in response to inflammation and is purported to be a risk factor for atherogenesis. We recently demonstrated that a scavenger receptor, lectin-like oxidized LDL receptor (LOX-1), is a receptor for CRP. In light of the overlapping ligand spectrum of scavenger receptors such as modified LDL, bacteria, and advanced glycation end products, we examined whether other scavenger receptors recognize CRP.
C-reactive protein (CRP), 1 which is synthesized by hepatocytes in response to inflammation and tissue damage (1 ) , binds to various ligands exposed on damaged tissues or bacteria promoting phagocytosis and complement activation with C1q (1, 2 ) . Plasma CRP concentrations may rise as much as 1000-fold during infection or inflammation (3 ) . In addition, CRP concentrations, within the reference range, can predict cardiovascular diseases (4, 5 ) , and there is a good correlation between plasma CRP concentrations and the degree of atherosclerosis in hypercholesterolemic rabbits (6 ) .
Fc␥ receptors CD16, CD32, and CD64 have been reported as the receptors for CRP (7) (8) (9) . In addition, we recently demonstrated that CRP increases vascular permeability through a direct binding to lectin-like oxidized LDL receptor (LOX-1), which is expressed in endothelial cells (10 ) . Members of the scavenger receptor family, such as class A scavenger receptor (SR-A), CD36, LOX-1, and scavenger receptor B-I (SR-BI), recognize common ligands such as modified LDL, bacteria, and advanced glycation end products, and they are thought to affect the progression of atherosclerosis (11, 12 ) . In this study, to further elucidate the atherogenic properties of CRP, we addressed whether other scavenger receptors are involved in the recognition of CRP.
Human sera with high and normal concentrations of CRP were obtained from Dako. Human CRP purified from pleural fluid was purchased from Chemicon (AG723). Sodium azide in the solution was extensively removed by dialyzing 3 times against a 3000-fold volume of Dulbecco's PBS (Wako). Gram-negative bacterial endotoxins were undetectable by limulus amebocyte lysate (Associates of Cape Cod), which can detect as little as 0.03 endotoxin units per mL endotoxins. CRP was fluorescently labeled with CypHer5E (GE Healthcare) and dialyzed 3 times against a 3000-fold volume of PBS.
COS-7 cells maintained with Dulbecco's modified Eagle's medium (DMEM; Invitrogen)/10% fetal bovine serum (FBS) were seeded 1 day before transfection. After reaching 80%-90% confluency, we transfected the cells with the plasmid using Lipofectamin 2000 transfection reagent (Invitrogen). We used the following cDNAs: human LOX-1 (GenBank NM002543), SR-A (GenBank NM002445), CD36 (GenBank NM000072), SR-BI (GenBank NM005505), CD68 (GenBank NM001251), and dectin-1 (GenBank NM197947), which were subcloned into pcDNA6.2/V5/GW/D-TOPO expression vector (Invitrogen). We used pcDNA3.1/V5-His/lacZ (Invitrogen) as a control. After 48 h, we washed the cells with DMEM:1% antibiotics and antimycotic (AbAm; Invitrogen). We replaced the medium with CypHer5E-CRP-containing DMEM/1% AbAm and incubated the cells for 2 h at 37°C. After washing with PBS, the cells were fixed with phosphate-buffered formalin (Wako) and permeabilized with 0.1% Triton X-100/PBS. We detected the expression of each receptor by immunostaining with anti-V5 antibody (Nacalai Tesque) combined with Alexa 488 antimouse IgG (Invitrogen). The nuclei of the cells were counterstained with 0.5 mg/L 4Ј,6-diamidino-2-phenylindole (DAPI) (Sigma). We divided the fluorescence intensities of CypHer5E and Alexa 488 by the cell number in a field, then divided the CypHer5E-CRP fluorescence intensity in the field by the Alexa 488 fluorescence value. These quantitative analyses were performed with an IN Cell Analyzer 1000 system (GE Healthcare).
We prepared recombinant human SR-A (amino acids 76 -358) as described for LOX-1 (10 ). Recombinant human SR-A (0.1 g) or BSA (0.1 g, Sigma) was immobilized to each well of 384-well plates (High Bind; Corning) by incubating at 4°C in PBS overnight. After 2 washes with PBS, the plates were blocked with 80 L of 20% ImmunoBlock (DS Pharma)/PBS at 4°C for 8 h. After washing twice with PBS, we added CRP in the reaction buffer (10 mmol/L HEPES, 150 mmol/L NaCl, 2 mmol/L CaCl 2 , 1% BSA, pH 7.0) to each well and incubated them at 4°C overnight. We detected the binding of CRP with a TMB Peroxidase EIA Substrate kit (Bio-Rad) as described for LOX-1 (10 ). We obtained small interfering RNA (siRNA) duplex oligoribonucleotides targeting the SR-A coding region (GenBank NM002445) from Invitrogen and used stealth RNAi duplex (Invitrogen) as a negative control. The siRNA sequences were as follows: 5Ј-GAUAUAACUCAAAGUCUCACGGGAA-3Ј, 5Ј-U UCCCGUGAGACUUUGAGUUAUAUC-3Ј and 5Ј-C AGACCUUGAGAAAUAUCACUUUAA-3Ј, 5Ј-UUA AAGUGAUAUUUCUCAAGGUCUG-3Ј.
THP-1 cells were maintained with 10% FBS/1% AbAm/20 mol/L mercaptoethanol:RPMI 1640 and differentiated with 100 nmol/L phorbol 12-myristate 13-acetate (PMA) (Sigma) for 48 h. We transfected the cells with siRNA oligos or control siRNA using Lipofectamin 2000 transfection reagent (Invitrogen) according to the manufacturer's instruction. After incubation at 37°C for 24 h, we washed the cells with RPMI 1640/1% AbAm and replaced the medium with CypHer5E-CRP-containing RPMI 1640/1% AbAm, and the cells were incubated for 2 h. After washing with PBS, the cells were fixed with phosphate-buffered formalin (Wako) and permeabilized with 0.1% Triton X-100/PBS. We detected the effects of downregulation of SR-A gene expression by immunostaining with anti-SR-A antibody (SRA-C6; Trans Genic Inc) combined with Alexa 488 antimouse IgG. For detection of Fc␥ receptors, we used anti-CD32 antibody (AT10; Santa Cruz) and anti-CD64 antibody (10.1; Santa Cruz). For CRP detection, we used anti-CRP antibody (Bethyl). The nuclei of the cells were counterstained with 0.5 mg/L DAPI. We divided the fluorescence intensities of CypHer5E and Alexa 488 by the cell number in a field. Quantitative analysis was performed with an IN Cell Analyzer 1000 system. All transfections were performed in triplicate.
All data are presented as mean (SE). Statistical analysis was performed with Student t-test. A P value Ͻ0.05 was considered statistically significant.
We examined whether CRP binds to scavenger receptors: LOX-1, SR-A, CD36, SR-BI, CD68, and dectin-1. Dectin-1 has the closest structural similarity to LOX-1 and belongs to C-type lectin-like molecule, although it is not a member of scavenger receptors.
Alexa546-labeled CRP at the concentration of 1 mg/L at 4°C bound significantly to LOX-1-expressing cells (P Ͻ 0.01) but bound poorly to the cells expressing the other receptors (Supplemental Fig. 1 , which accompanies the online version of this article at www. clinchem.org/content/vol56/issue3). Cellular uptake of CypHer5E-labeled CRP, which shows fluorescence after endocytosis, was significantly higher in SR-Aexpressing cells, in a dose-dependent manner (1-30 mg/L), as well as in LOX-1-expressing cells, compared with cells expressing the other receptors (Fig. 1) . Immunostaining with anti-V5 antibody revealed that all the receptors were expressed at a similar level in the respective cells.
Using anti-CRP antibody, we confirmed that nonlabeled CRP was also taken up by SR-A-expressing COS-7 cells. We further observed a significant binding of nonlabeled CRP (0.1-1 mg/L) to immobilized recombinant SR-A (P Ͻ 0.01) (online Supplemental Fig.  2 ). The binding was not affected by polymyxin B (5 mg/L), suggesting that it did not depend on the presence of endotoxin. Importantly, native CRP contained in human serum showed significant binding to SR-A, as well as to LOX-1 (P Ͻ 0.01) (online Supplemental  Fig. 3 ). The binding was dependent on the concentration of CRP in the serum, suggesting that SR-A and LOX-1 have a capacity to bind to a native form of CRP in serum in the presence of other plasma proteins. These results indicate that SR-A and LOX-1 are the receptors for CRP among the examined receptors.
Because SR-A works in the monocyte-macrophage system, we assessed whether CRP is taken up by macrophages via SR-A. We used a human monocytic cell line, THP-1, after inducing differentiation into macrophage by the treatment of PMA (13 ) . In PMA-treated THP-1 cells, CypHer5E-CRP was taken up in a dosedependent manner (0.3-30 mg/L). SR-A expression and CRP uptake were concomitantly suppressed by 2 different siRNAs targeting SR-A, but not by control siRNA ( Table 1 ). The siRNA targeting SR-A did not affect the expression of Fc␥ receptors (data not shown), indicating that CRP is taken up mainly via SR-A in a macrophage cell line, at least under these conditions.
The ligand specificity of the scavenger receptor family overlaps considerably (11, 12 ) , and while all can bind to oxidized LDL, only SR-A or LOX-1 bound to CRP. Interestingly, dectin-1, the most structurally similar molecule to LOX-1, did not bind to CRP.
Using a monoclonal antibody, a previous report suggested the presence of an unknown receptor other than Fc␥ receptors in macrophages (14 ) . It has been reported that fucoidin, a ligand for SR-A, inhibits the in vivo CRPpromoted uptake of oxidized LDL (15 ) . SR-A might be the unidentified CRP receptor. Fc␥ receptors and SR-A are under different regulation of gene expression. In fact, in response to differentiation stimulus of PMA, the expression of SR-A is strongly induced, whereas the expression of Fc␥ receptors is suppressed (16, 17 ) . Conversely, stimulation by interferon-␥ enhances the expression of Fc␥ receptors but suppresses the expression of SR-A (18 ). These results suggest that Fc␥ receptors and SR-A would work in the cells stimulated by different molecules.
Interestingly, the activity of SR-A as CRP receptor was more pronounced in the uptake of CRP, whereas LOX-1 showed strong activity in both binding and uptake. Because SR-A works in phagocytes, the CRP uptake activity of SR-A is reasonable. CRP was originally identified as a binding protein for bacterial component C-polysaccharide (3 ) . SR-A may function to engulf bacteria, viruses, and harmful substances opsonized by CRP in a context of innate immunity.
Related to epidemiological risk factors for cardiovascular disease, the presence of CRP in atheroma has been reported in both rabbits and humans (6 ) . Furthermore, the colocalization of CRP and SR-A in macrophages in atheromas has been reported (19 ) . Taking these reports together with the present results, SR-A-mediated CRP uptake by macrophages in atheromas might affect the foam cell formation and progression of atherosclerotic disease. 
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